American International Group Inc. Sells 429 Shares of Catalent, Inc. (NYSE:CTLT)

American International Group Inc. decreased its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,627 shares of the company’s stock after selling 429 shares during the period. American International Group Inc.’s holdings in Catalent were worth $2,230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of CTLT. Envestnet Asset Management Inc. grew its position in shares of Catalent by 47.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 402,172 shares of the company’s stock valued at $18,311,000 after acquiring an additional 129,385 shares during the period. Hsbc Holdings PLC grew its position in shares of Catalent by 43.1% during the 3rd quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock valued at $8,803,000 after acquiring an additional 58,240 shares during the period. Dark Forest Capital Management LP bought a new stake in shares of Catalent during the 3rd quarter valued at $500,000. Mariner LLC lifted its stake in shares of Catalent by 18.8% during the 3rd quarter. Mariner LLC now owns 13,079 shares of the company’s stock valued at $595,000 after buying an additional 2,073 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Catalent by 13.6% during the 3rd quarter. Northern Trust Corp now owns 2,160,603 shares of the company’s stock valued at $98,372,000 after buying an additional 258,482 shares in the last quarter.

Catalent Stock Down 0.6 %

Shares of CTLT stock opened at $56.14 on Wednesday. The company’s fifty day simple moving average is $55.53 and its two-hundred day simple moving average is $53.58. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.16 billion, a P/E ratio of -9.20, a PEG ratio of 6.79 and a beta of 1.20. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Analysts predict that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CTLT. Stephens restated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. StockNews.com began coverage on shares of Catalent in a research note on Saturday. They set a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Catalent currently has a consensus rating of “Hold” and an average target price of $54.05.

Insider Activity at Catalent

In related news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.31% of the stock is currently owned by insiders.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.